In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellipharmaceutics International Inc.

www.intellipharmaceutics.com

Latest From Intellipharmaceutics International Inc.

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Opioid Sponsors Enter 2019 At A Crossroads

Recent regulatory trends at US FDA offer no clear path to success for sponsors developing opioids. As 2018 concludes with only one approval and at least five rejections, firms will need new strategies if they hope to bring the analgesics to market. 
Research & Development Neurology

Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel

FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
Advisory Committees Neurology

Opioid Dispute Resolution Denied By US FDA In Part Because Of Dueling Requests

Pharmaceutical Manufacturing Research Services argued that its immediate-release oxycodone should be approved with abuse-deterrent labeling while simultaneously asserting that abuse-deterrent labeling should only be permitted based on postmarketing studies, FDA notes.
Complete Response Letters Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Intellipharmaceutics International Inc.
  • Senior Management
  • Isa Odidi, PhD, Chmn., CEO & CSO
    Andrew Patient, CFO
    Amina Odidi, PhD, Pres., COO & CSO
    Christian Akyempon, VP, Commercial Ops.
    Patrick N Yat, PhD, VP, Chemistry & Analytical Services
  • Contact Info
  • Intellipharmaceutics International Inc.
    Phone: (416) 798-3001
    30 Worcester Rd.
    Toronto, M9W 5X2
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register